ALK and non-small cell lung carcinoma: The range of IC50 doses for the IBC cell lines that express either ALK or cMET mRNA is consistent with the IC50 concentration of Crizotinib in the H2888 NSCLC cell line, which has an EML4-ALK translocation, and for the IMR-32 neuroblastoma cell line, IMR-32 (Table 2) which harbors full length wild type oncogenic ALK.